YZ-0213

YZ-0213 is a preclinical-stage small molecule inhibitor of the **NF-κB** (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway. Developed by **Guangdong Yinzhu Pharmaceutical Technology**, the compound is being investigated for the treatment of **pancreatic cancer**, specifically intended for use in combination with the standard-of-care chemotherapy agent gemcitabine. NF-κB is a transcription factor that plays a pivotal role in regulating genes involved in inflammation, cell proliferation, and apoptosis. In pancreatic ductal adenocarcinoma, constitutive activation of NF-κB is associated with tumor progression and resistance to gemcitabine-induced apoptosis. By targeting this pathway, YZ-0213 aims to sensitize tumor cells to chemotherapy and improve therapeutic outcomes in pancreatic cancer patients.